BioSpace News Archive

The genetic test, a first of its kind, identifies specific DNA biomarkers in order to gauge the risk and potential of adverse reactions toward hallucinogenic drugs.

In recent years, methamphetamine use and related harms have increased in many communities, especially in Western and Central Canada.

Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, announced a partnership with University of California, San Francisco to develop non-invasive, individualized, peripheral nerve stimulation therapies that leverage Cala Health’s neuromodulation and data science platform technology.

DCN Dx, an international provider of point-of-care diagnostics development, products, and educational programming, today announced it has completed its acquisition of PortaScience, Inc., a dry chemistry-focused point-of-care diagnostics development company based here

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of Kishen Mehta, Portfolio Manager at Suvretta Capital Management, LLC, to its Board of Directors (“Board”).

LENZ Therapeutics today emerged from stealth mode with a $47 million Series A financing from Versant Ventures and RA Capital Management.

PhaseBio to host conference call today at 5:30 am PST / 8:30 am EST that it has entered into an exclusive licensing agreement with Alfasigma S.p.A.

Agenus Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted Agenus’ Biologics License Application (BLA) for balstilimab.

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has released IPFsym version 1A, quantitative systems pharmacology modeling software to support the development of treatments for idiopathic pulmonary fibrosis

Blue Water Vaccines, Inc., a biopharmaceutical company, announced that it has engaged the services of former Congressman Theodore Scott Yoho, as the Head of Business Development and veteran vaccine manufacturing specialist Andrew D. Skibo as Global Head of Biologics Operations.